SCHEMBL1167427

SCHEMBL1167427

CC(C)Oc1ccc(C(=O)n2nc(N)nc2Nc2ccc(N3CCCCC3)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ KDM4E B2RXH2 2/20 0.59
▸ ALDH1A1 P00352 6/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ ALOX15 P16050 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ USP2 O75604 1/20 0.57
▸ RAB9A P51151 3/20 0.43
▸ MCL1 Q07820 3/20 0.43
▸ NR4A1 P22736 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ F12 P00748 3/20 0.41
▸ GLA P06280 1/20 0.41
▸ LCK P06239 1/20 0.40
▸ BTK Q06187 1/20 0.40
▸ MAPK7 Q13164 1/20 0.40
▸ MC4R P32245 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1168610 0.99 MAPT (0.58) MAPTSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL1168134 0.92 MAPT (0.48) MAPTSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL1167935 0.92 ALDH1A1 (0.50) MAPTSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL1167909 0.86 MAPT (0.42) MAPTSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL1168941 0.85 NPC1 (0.52) MAPTSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL1167171 0.85 P2RX3 (0.46) MAPTALDH1A1KMT2AGLAMAPK7
SCHEMBL1167486 0.85 MAPT (0.59) MAPTSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL1166889 0.85 AXL (0.48) MAPTKDM4EALDH1A1TP53THRB
SCHEMBL1168104 0.84 MAPT (0.58) MAPTSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL1167609 0.84 AXL (0.47) MAPTKDM4EALDH1A1TP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2007-09-13 — — US claimed
US-8389557-B2 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2013-03-05 — — US disclosed
US-20110082131-A1 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2011-04-07 — — US disclosed
US-7884119-B2 protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation RIGEL PHARMACEUTICALS, INC. (US) 2011-02-08 — — US disclosed
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082131-A1 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS AXL, TYRO3, FLT3 MAPT 2385/4885SMN1; SMN2 3462/4885KDM4E 4332/4885
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors AXL, TYRO3, FLT3 MAPT 2368/4885SMN1; SMN2 4319/4885KDM4E 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback